The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Demyelination versus remyelination in progressive multiple sclerosis
Abstract
The causes of incomplete remyelination in progressive multiple sclerosis are unknown, as are the pathological correlates of the different clinical characteristics of patients with primary and secondary progressive disease. We analysed brains and spinal cords from 51 patients with progressive multiple sclerosis by planimetry. Thirteen patients with primary progressive disease were compared with 34 with secondary progressive disease. In patients with secondary progressive multiple sclerosis, we found larger brain plaques, more demyelination in total and higher brain loads of active demyelination compared with patients with primary progressive disease. In addition, the brain density of plaques with high-grade inflammation and active demyelination was highest in secondary progressive multiple sclerosis and remained ~18% higher than in primary progressive multiple sclerosis after adjustments for other plaque types and plaque number (P<0.05). Conversely, the proportion of remyelinated shadow plaques (P<0.05) and the overall remyelination capacity (P<0.01) per brain were higher in primary, compared with secondary, progressive multiple sclerosis. By contrast, there were no group differences in the brain load or frequency of low-grade inflammatory plaques with slowly expanding demyelination. Spinal cord lesion loads and remyelination capacity were also comparable in the two patient groups. Remyelinated areas were more vulnerable than the normal-appearing white matter to new demyelination, including active demyelination in secondary progressive multiple sclerosis. 'Recurrent' slowly expanding demyelination, affecting remyelinated areas, and the load of slowly expanding demyelination correlated with incomplete remyelination in both groups. In turn, incomplete remyelination in the spinal cord correlated with higher disease-related disability (determined retrospectively; r = -0.53; P<0.05 for remyelination capacity versus disease severity). By contrast, such a correlation was not observed in the brain. We propose that regulatory and reparative properties could protect the white matter of the brain in patients with primary progressive multiple sclerosis. These patients may, thereby, be spared symptoms until the spinal cord is affected. By contrast, recurrent active demyelination of repaired myelin could explain why similar symptoms often develop in consecutive relapses in relapsing-remitting/secondary progressive multiple sclerosis. Our data also indicate that slowly expanding demyelination may irreparably destroy normal and repaired myelin, supporting the concept of slowly expanding demyelination as an important pathological correlate of clinical progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovering Statistics Using SPSS
Field, A. P., & Miles, J. N. V. (2000) · Medical Entomology and Zoology · Cited by 28,288
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationThe relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Self-citationMultiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity
Roxburgh, R. H. S. R., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., Achiti, I., Confavreux, C., Coustans, M., le Page, E., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000156155.19270.f8 · Cited by 963
Self-citationMultiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
Self-citationNatural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 905
Kuhlmann, T., Miron, V., Cuo, Q., Wegner, C., Antel, J., & Bruck, W. (2008) · Brain · doi:10.1093/brain/awn096 · Cited by 864
Primary-progressive multiple sclerosis
Miller, D. H., & Leary, S. M. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70243-0 · Cited by 818
Cited by
Pathological mechanisms in progressive multiple sclerosis
Mahad, D. H., Trapp, B. D., & Lassmann, H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70256-x · Cited by 1,137
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Self-citationLassmann, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028936 · Cited by 937
“…by several factors, such as the presence of progenitor cells, their potential to differentiate into mature myelinating oligodendrocytes (Chang et al. 2002), the presence and functional properties of axons, and the occurrence of repeated demyelination of remyelinated areas (Bramow et al. 2010).”
BackgroundSelf-citationFrischer, J. M., Weigand, S. D., Guo, Y., Kale, N., Parisi, J. E., Pirko, I., Mandrekar, J., Bramow, S., Metz, I., Brück, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24497 · Cited by 728
Self-citationMyelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H. L., & Lassmann, H. (2017) · Brain · doi:10.1093/brain/awx113 · Cited by 684
“In contrast to classical active lesions, macrophages were rare or absent in the demyelinated core of slowly expanding lesions and cells with an anti-inflammatory (M2) phenotype were extremely rare in these lesions, which also did not show signs of remyelination (Bramow et al., 2010).”
ResultSelf-citationAn updated histological classification system for multiple sclerosis lesions
Kuhlmann, T., Ludwin, S., Prat, A., Antel, J., Brück, W., & Lassmann, H. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1653-y · Cited by 692
“Remyelinated lesion areas are even present in active and demyelinating lesions; however, the myelin may not be stable and subsequently subject to new waves of demyelination [9, 47].”
BackgroundSelf-citationPathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Lassmann, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03116 · Cited by 663
Self-citationProgressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
Association between pathological and MRI findings in multiple sclerosis
Filippi, M., Rocca, M. A., Barkhof, F., Brück, W., Chen, J. T., Comi, G., DeLuca, G., De Stefano, N., Erickson, B. J., Evangelou, N., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70003-0 · Cited by 486
Self-citationSlow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging
Dal-Bianco, A., Grabner, G., Kronnerwetter, C., Weber, M., Höftberger, R., Berger, T., Auff, E., Leutmezer, F., Trattnig, S., Lassmann, H., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1636-z · Cited by 463
“Partially remyelinated lesions showed areas of remyelination and complete demyelination [8].”
BackgroundSelf-citationPathology of Demyelinating Diseases
Popescu, B. F. G., & Lucchinetti, C. F. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132443 · Cited by 397
Self-citationThe Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review
Ma, W.-T., Gao, F., Gu, K., & Chen, D.-K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01140 · Cited by 361
Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions
Absinta, M., Sati, P., Schindler, M., Leibovitch, E. C., Ohayon, J., Wu, T., Meani, A., Filippi, M., Jacobson, S., Cortese, I. C. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86198 · Cited by 327
“Among chronically demyelinated lesions, the pathologically described chronic active and slowly expanding (or “smoldering”) lesions (9) might be considered the worst-case scenario of remyelination failure (10), with persistent inflammatory infiltration (macrophages/microglia) and evidence of ongoing demyelination at th…”
BackgroundPathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Peruzzotti-Jametti, L., Bernstock, J. D., Vicario, N., Costa, A. S. H., Kwok, C. K., Leonardi, T., Booty, L. M., Bicci, I., Balzarotti, B., Volpe, G., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.01.020 · Cited by 285
Remyelination therapies: a new direction and challenge in multiple sclerosis
Plemel, J. R., Liu, W.-Q., & Yong, V. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.115 · Cited by 281
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis
Tutuncu, M., Tang, J., Zeid, N. A., Kale, N., Crusan, D. J., Atkinson, E. J., Siva, A., Pittock, S. J., Pirko, I., Keegan, B. M., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512451510 · Cited by 267
Self-citationPathology of Multiple Sclerosis: Where Do We Stand?
Popescu, B. F. G., Pirko, I., & Lucchinetti, C. F. (2013) · Continuum · doi:10.1212/01.con.0000433291.23091.65 · Cited by 261
Self-citationFunctional polarization of neuroglia: Implications in neuroinflammation and neurological disorders
Jha, M. K., Lee, W.-H., & Suk, K. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.11.003 · Cited by 260
Multiple sclerosis animal models: a clinical and histopathological perspective
Kipp, M., Nyamoya, S., Hochstrasser, T., & Amor, S. (2017) · Brain Pathology · doi:10.1111/bpa.12454 · Cited by 226
Pathology and disease mechanisms in different stages of multiple sclerosis
Lassmann, H. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.05.010 · Cited by 224
Self-citationMechanisms of lysophosphatidylcholine‐induced demyelination: A primary lipid disrupting myelinopathy
Plemel, J. R., Michaels, N. J., Weishaupt, N., Caprariello, A. V., Keough, M. B., Rogers, J. A., Yukseloglu, A., Lim, J., Patel, V. V., Rawji, K. S., et al. (2018) · Glia · doi:10.1002/glia.23245 · Cited by 220
Elliott, C., Wolinsky, J. S., Hauser, S. L., Kappos, L., Barkhof, F., Bernasconi, C., Wei, W., Belachew, S., & Arnold, D. L. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518814117 · Cited by 217
Cortical remyelination: A new target for repair therapies in multiple sclerosis
Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., Yong, V. W., Fox, R. J., Kidd, G. J., & Trapp, B. D. (2012) · Annals of Neurology · doi:10.1002/ana.23693 · Cited by 216
Mechanisms of white matter damage in multiple sclerosis
Lassmann, H. (2014) · Glia · doi:10.1002/glia.22597 · Cited by 191
“One important additional reason for the low incidence of stable shadow plaques despite extensive attempts of remyelination in early MS lesions is that remyelinated areas are particularly vulnerable for new demyelination (Bramow et al., 2010).”
BackgroundSelf-citationCNS remyelination and inflammation: From basic mechanisms to therapeutic opportunities
Franklin, R. J. M., & Simons, M. (2022) · Neuron · doi:10.1016/j.neuron.2022.09.023 · Cited by 184
Microglia regulation of central nervous system myelin health and regeneration
Kent, S. A., & Miron, V. E. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00907-4 · Cited by 183
De Feo, D., Merlini, A., Laterza, C., & Martino, G. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328352ec45 · Cited by 181
Dulamea, A. O. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-47861-6_7 · Cited by 128
Cortical remyelination is heterogeneous in multiple sclerosis
Strijbis, E. M. M., Kooi, E.-J., van der Valk, P., & Geurts, J. J. G. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx023 · Cited by 82
Microglia promote remyelination independent of their role in clearing myelin debris
Baaklini, C. S., Ho, M. F. S., Lange, T., Hammond, B. P., Panda, S. P., Zirngibl, M., Zia, S., Himmelsbach, K., Rana, H., Phillips, B., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113574 · Cited by 84
Sex differences in EAE reveal common and distinct cellular and molecular components
Wiedrick, J., Meza-Romero, R., Gerstner, G., Seifert, H., Chaudhary, P., Headrick, A., Kent, G., Maestas, A., Offner, H., & Vandenbark, A. A. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104242 · Cited by 55
Palumbo, S., Toscano, C. D., Parente, L., Weigert, R., & Bosetti, F. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07363.x · Cited by 46
“Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS leading to permanent cognitive and motor disabilities and characterized by inflammation, demyelination, oligodendrocyte loss, and axonal pathology (Kutzelnigg et al. 2005; Tumani et al. 2009; Bramow et al. 2010).”
Ammitzbøll, C., Dyrby, T. B., Börnsen, L., Schreiber, K., Ratzer, R., Romme Christensen, J., Iversen, P., Magyari, M., Lundell, H., Jensen, P. E. H., et al. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104854 · Cited by 20
Self-citationScalabrino, G. (2022) · Biomedicines · doi:10.3390/biomedicines10040815 · Cited by 10
Metadata
- Authors
- Bramow, S., Frischer, J. M., Lassmann, H., Koch-Henriksen, N., Lucchinetti, C. F., Sørensen, P. S., & Laursen, H.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09-20
- Volume
- 133
- Issue
- 10
- Pages
- 2983-2998
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2097866416
- Cited by
- 319
- References
- 47
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.